Publikationen, an denen er mitarbeitet Isidoro Martínez González (20)

2023

  1. Corrigendum to “PBMCs gene expression signature of advanced cirrhosis with high risk for clinically significant portal hypertension in HIV/HCV coinfected patients: A cross-control study” [Biomed. Pharmacother. 159 (2023) 114220] (Biomedicine & Pharmacotherapy (2023) 159, (S0753332223000082), (10.1016/j.biopha.2023.114220))

    Biomedicine and Pharmacotherapy

  2. Diagnostic Performance of the HCV Core Antigen Test To Identify Hepatitis C in HIV-Infected Patients: a Systematic Review and Meta-Analysis

    Journal of clinical microbiology, Vol. 61, Núm. 1, pp. e0133122

  3. Diagnostic performance of hepatitis C core antigen assay to identify active infections: A systematic review and meta-analysis

    Reviews in Medical Virology, Vol. 33, Núm. 3

  4. IL7RA rs10491434 polymorphism is related to spontaneous HIV infection control in naïve HIV-infected patients: A retrospective study

    Journal of Medical Virology, Vol. 95, Núm. 11

  5. IRF5-TNOP3 polymorphisms are associated with elite control of HIV infection: A retrospective study

    Journal of medical virology, Vol. 95, Núm. 6, pp. e28841

  6. PBMCs gene expression signature of advanced cirrhosis with high risk for clinically significant portal hypertension in HIV/HCV coinfected patients: A cross-control study

    Biomedicine and Pharmacotherapy, Vol. 159

  7. TNFAIP3-interacting protein 1 polymorphisms and their association with symptomatic human respiratory syncytial virus infection and bronchiolitis in infants younger than one year from South Africa: A case-control study

    International Journal of Infectious Diseases, Vol. 136, pp. 107-110

2022

  1. Meta-analysis: diagnostic accuracy of hepatitis C core antigen detection during therapy with direct-acting antivirals

    Alimentary Pharmacology and Therapeutics, Vol. 56, Núm. 8, pp. 1224-1234

  2. Metabolic Profiling at COVID-19 Onset Shows Disease Severity and Sex-Specific Dysregulation

    Frontiers in Immunology, Vol. 13

  3. Metabolomic changes after DAAs therapy are related to the improvement of cirrhosis and inflammation in HIV/HCV-coinfected patients

    Biomedicine and Pharmacotherapy, Vol. 147

  4. Similar humoral immune responses against the SARS-CoV-2 spike protein in HIV and non-HIV individuals after COVID-19

    Journal of Infection

2021

  1. HCV Cure With Direct-Acting Antivirals Improves Liver and Immunological Markers in HIV/HCV-Coinfected Patients

    Frontiers in Immunology, Vol. 12

  2. HCV eradication with IFN-based therapy does not completely restore gene expression in PBMCs from HIV/HCV-coinfected patients

    Journal of Biomedical Science, Vol. 28, Núm. 1

  3. TRPM5 rs886277 polymorphism predicts hepatic fibrosis progression in non-cirrhotic HCV-infected patients

    Journal of Clinical Medicine, Vol. 10, Núm. 3, pp. 1-10

2020

  1. Near normalization of peripheral blood markers in HIV-infected patients on long-term suppressive antiretroviral therapy: a case-control study

    AIDS (London, England), Vol. 34, Núm. 13, pp. 1891-1897

2019

  1. Genetic variants upstream of TNFAIP3 in the 6q23 region are associated with liver disease severity in HIV/HCV-coinfected patients: A cross-sectional study

    Infection, Genetics and Evolution, Vol. 67, pp. 112-120

  2. Impact of darc rs12075 variants on liver fibrosis progression in patients with chronic hepatitis c: A retrospective study

    Biomolecules, Vol. 9, Núm. 4

  3. TNFAIP3, TNIP1, and MyD88 polymorphisms predict septic-shock-related death in patients who underwent major surgery

    Journal of Clinical Medicine, Vol. 8, Núm. 3

2018

  1. Vitamin D in human immunodeficiency virus infection: Influence on immunity and disease

    Frontiers in Immunology

2016

  1. Relationship of TRIM5 and TRIM22 polymorphisms with liver disease and HCV clearance after antiviral therapy in HIV/HCV coinfected patients

    Journal of Translational Medicine, Vol. 14, Núm. 1